



US009034376B2

(12) **United States Patent**
Wright et al.

(10) **Patent No.:** **US 9,034,376 B2**
(45) **Date of Patent:** ***May 19, 2015**

(54) **PHARMACEUTICAL FORMULATION**
CONTAINING GELLING AGENT

(2013.01); **A61K 47/38** (2013.01); **A61K 47/36**
(2013.01); **A61K 47/10** (2013.01); **A61K 45/06**
(2013.01); **A61K 31/192** (2013.01); **A61K**
9/1652 (2013.01); **A61K 47/26** (2013.01)

(71) Applicants: **Purdue Pharma L.P.**, Stamford, CT
(US); **The P.F. Laboratories, Inc.**,
Totowa, NJ (US); **Purdue**
Pharmaceuticals L.P., Wilson, NC (US)

(58) **Field of Classification Search**
None
See application file for complete search history.

(72) Inventors: **Curtis Wright**, Rockport, MA (US);
Benjamin Oshlack, Boca Raton, FL
(US); **Christopher Breder**, Bethesda,
MD (US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(73) Assignees: **Purdue Pharma L.P.**, Stamford, CT
(US); **The P.F. Laboratories, Inc.**,
Totowa, NJ (US); **Purdue**
Pharmaceuticals L.P., Wilson, NC (US)

| | | |
|-------------|---------|--------------------|
| 3,065,143 A | 11/1962 | Christenson et al. |
| 3,133,132 A | 5/1964 | Loeb et al. |
| 3,173,876 A | 3/1965 | Zobrist et al. |
| 3,260,646 A | 7/1966 | Paulsen et al. |
| 3,276,586 A | 10/1966 | Rosaen |
| 3,541,005 A | 11/1970 | Strathmann et al. |
| 3,541,006 A | 11/1970 | Bixler et al. |
| 3,546,876 A | 12/1970 | Fokker et al. |
| 3,845,770 A | 11/1974 | Theeuwes et al. |
| 3,916,889 A | 11/1975 | Russell |
| 3,965,256 A | 6/1976 | Leslie |
| 3,980,766 A | 9/1976 | Shaw et al. |
| 4,063,064 A | 12/1977 | Saunders et al. |
| 4,070,494 A | 1/1978 | Hoffmeister et al. |
| 4,088,864 A | 5/1978 | Theeuwes et al. |
| 4,160,020 A | 7/1979 | Ayer et al. |
| 4,175,119 A | 11/1979 | Porter |
| 4,200,098 A | 4/1980 | Ayer et al. |

(*) **Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **14/460,134**

(22) Filed: **Aug. 14, 2014**

(65) **Prior Publication Data**

US 2014/0357657 A1 Dec. 4, 2014

Related U.S. Application Data

(63) Continuation of application No. 14/255,502, filed on
Apr. 17, 2014, now Pat. No. 8,871,265, which is a
continuation of application No. 13/726,324, filed on
Dec. 24, 2012, which is a continuation of application
No. 13/349,449, filed on Jan. 12, 2012, now Pat. No.
8,337,888, which is a continuation of application No.
12/653,115, filed on Dec. 8, 2009, now abandoned,
which is a continuation of application No. 10/214,412,
filed on Aug. 6, 2002.

(60) Provisional application No. 60/310,534, filed on Aug.
6, 2001.

(51) **Int. Cl.**

| | |
|--------------------|-----------|
| A61K 9/20 | (2006.01) |
| A61K 31/167 | (2006.01) |
| A61K 9/00 | (2006.01) |
| A61K 31/439 | (2006.01) |
| A61K 31/485 | (2006.01) |
| A61K 47/38 | (2006.01) |
| A61K 47/36 | (2006.01) |
| A61K 47/10 | (2006.01) |
| A61K 45/06 | (2006.01) |
| A61K 31/192 | (2006.01) |
| A61K 9/16 | (2006.01) |
| A61K 47/26 | (2006.01) |

(52) **U.S. Cl.**

CPC **A61K 31/167** (2013.01); **A61K 9/2013**
(2013.01); **A61K 9/205** (2013.01); **A61K**
9/2054 (2013.01); **A61K 9/0002** (2013.01);
A61K 31/439 (2013.01); **A61K 31/485**

(Continued)

FOREIGN PATENT DOCUMENTS

| | | |
|----|------------|--------|
| EP | 0318262 A1 | 5/1989 |
| EP | 0661045 | 7/1995 |

(Continued)

OTHER PUBLICATIONS

Paragraph IV Patent Certification Notice for ANDA 202434 (2011).
Paragraph IV Patent Certification Notice for ANDA 203235 (2011).
Paragraph IV Patent Certification Notice for ANDA 202372 (2011).
Paragraph IV Patent Certification Notice for ANDA 202483 (2011).
Paragraph IV Patent Certification Notice for ANDA 202762 (2011).
Paragraph IV Patent Certification Notice for Amendment to ANDA
202762 (2011).

(Continued)

Primary Examiner — Robert A Wax

Assistant Examiner — Olga V Tcherkasskaya

(74) *Attorney, Agent, or Firm* — Lowenstein Sandler LLP

(57) **ABSTRACT**

Disclosed in certain embodiments is a controlled release oral
dosage form comprising a therapeutically effective amount of
a drug susceptible to abuse together with one or more phar-
maceutically acceptable excipients; the dosage form further
including a gelling agent in an effective amount to impart a
viscosity unsuitable for administration selected from the
group consisting of parenteral and nasal administration to a
solubilized mixture formed when the dosage form is crushed
and mixed with from about 0.5 to about 10 ml of an aqueous
liquid; the dosage form providing a therapeutic effect for at
least about 12 hours when orally administered to a human
patient.

19 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | | |
|-----------|---|---------|-------------------|-----------|----|---------|---------------------|----------|
| 4,235,870 | A | 11/1980 | Leslie | 5,593,994 | A | 1/1997 | Batt et al. | |
| 4,285,987 | A | 8/1981 | Ayer et al. | 5,604,253 | A | 2/1997 | Lau et al. | |
| 4,293,539 | A | 10/1981 | Ludwig et al. | 5,604,260 | A | 2/1997 | Guay et al. | |
| 4,366,310 | A | 12/1982 | Leslie | 5,616,601 | A | 4/1997 | Khanna et al. | |
| 4,385,057 | A | 5/1983 | Bjork et al. | 5,639,476 | A | 6/1997 | Oshlack et al. | |
| 4,389,393 | A | 6/1983 | Schor et al. | 5,639,780 | A | 6/1997 | Lau et al. | |
| 4,424,205 | A | 1/1984 | LaHann et al. | 5,656,295 | A | 8/1997 | Oshlack et al. | |
| 4,443,428 | A | 4/1984 | Oshlack et al. | 5,667,805 | A | 9/1997 | Merrill et al. | |
| 4,457,933 | A | 7/1984 | Gordon et al. | 5,672,360 | A | 9/1997 | Sackler et al. | |
| 4,459,278 | A | 7/1984 | Porter | 5,679,650 | A | 10/1997 | Fukunaga et al. | |
| 4,588,580 | A | 5/1986 | Gale et al. | 5,681,585 | A | 10/1997 | Oshlack et al. | |
| 4,599,342 | A | 7/1986 | LaHann | 5,695,781 | A | 12/1997 | Zhang et al. | |
| 4,610,870 | A | 9/1986 | Jain et al. | 5,730,716 | A | 3/1998 | Beck et al. | 604/20 |
| 4,612,008 | A | 9/1986 | Wong et al. | 5,741,524 | A | 4/1998 | Staniforth et al. | |
| 4,666,705 | A | 5/1987 | DeCrosta et al. | 5,762,963 | A | 6/1998 | Byas-Smith | |
| 4,764,378 | A | 8/1988 | Keith et al. | 5,843,480 | A | 12/1998 | Miller et al. | |
| 4,765,989 | A | 8/1988 | Wong et al. | 5,849,240 | A | 12/1998 | Miller et al. | |
| 4,769,372 | A | 9/1988 | Kreek | 5,866,164 | A | 2/1999 | Kuczynski et al. | |
| 4,785,000 | A | 11/1988 | Kreek et al. | 5,879,705 | A | 3/1999 | Heafield et al. | |
| 4,806,341 | A | 2/1989 | Chien et al. | 5,891,471 | A | 4/1999 | Miller et al. | |
| 4,812,446 | A | 3/1989 | Brand | 5,891,919 | A | 4/1999 | Blum et al. | |
| 4,834,984 | A | 5/1989 | Goldie et al. | 5,914,131 | A | 6/1999 | Merrill et al. | |
| 4,844,909 | A | 7/1989 | Goldie et al. | 5,958,452 | A | 9/1999 | Oshlack et al. | |
| 4,861,598 | A | 8/1989 | Oshlack | 5,958,459 | A | 9/1999 | Chasin et al. | |
| 4,957,681 | A | 9/1990 | Klimesch et al. | 5,965,161 | A | 10/1999 | Oshlack et al. | |
| 4,970,075 | A | 11/1990 | Oshlack | 5,965,163 | A | 10/1999 | Miller et al. | |
| 4,990,341 | A | 2/1991 | Goldie et al. | 5,968,551 | A | 10/1999 | Oshlack et al. | |
| 5,026,556 | A | 6/1991 | Drust et al. | 6,024,982 | A | 2/2000 | Oshlack et al. | |
| 5,059,600 | A | 10/1991 | Gawin et al. | 6,120,751 | A | 9/2000 | Unger | 424/9.51 |
| 5,069,909 | A | 12/1991 | Sharma et al. | 6,124,282 | A | 9/2000 | Sellers et al. | |
| 5,111,942 | A | 5/1992 | Bernardin | 6,136,864 | A | 10/2000 | Nichols et al. | |
| 5,114,942 | A | 5/1992 | Gawin et al. | 6,143,322 | A | 11/2000 | Sackler et al. | |
| 5,130,311 | A | 7/1992 | Guillaumet et al. | 6,153,621 | A | 11/2000 | Hamann | |
| 5,149,538 | A | 9/1992 | Granger et al. | 6,162,467 | A | 12/2000 | Miller et al. | |
| 5,169,645 | A | 12/1992 | Shukla et al. | 6,223,075 | B1 | 4/2001 | Beck et al. | 604/20 |
| 5,202,128 | A | 4/1993 | Morella et al. | 6,228,863 | B1 | 5/2001 | Palermo et al. | |
| 5,215,758 | A | 6/1993 | Krishnamurthy | 6,245,357 | B1 | 6/2001 | Edgren et al. | 424/473 |
| 5,225,199 | A | 7/1993 | Hidaka et al. | 6,277,398 | B1 | 8/2001 | Caruso | |
| 5,232,934 | A | 8/1993 | Downs | 6,294,194 | B1 | 9/2001 | Horhota et al. | |
| 5,240,711 | A | 8/1993 | Hille et al. | 6,309,668 | B1 | 10/2001 | Bastin et al. | |
| 5,266,331 | A | 11/1993 | Oshlack et al. | 6,352,721 | B1 | 3/2002 | Faour | |
| 5,273,758 | A | 12/1993 | Royce | 6,375,957 | B1 | 4/2002 | Kaiko et al. | |
| 5,273,760 | A | 12/1993 | Oshlack et al. | 6,403,056 | B1 | 6/2002 | Unger | 424/9.51 |
| 5,286,493 | A | 2/1994 | Oshlack et al. | 6,419,954 | B1 | 7/2002 | Chu | |
| 5,290,816 | A | 3/1994 | Blumberg | 6,436,441 | B1 | 8/2002 | Sako et al. | |
| 5,321,012 | A | 6/1994 | Mayer et al. | 6,440,464 | B1 | 8/2002 | Hsia et al. | |
| 5,324,351 | A | 6/1994 | Oshlack et al. | 6,488,963 | B1 | 12/2002 | McGinity | |
| 5,330,766 | A | 7/1994 | Morella et al. | 6,491,949 | B2 | 12/2002 | Faour et al. | |
| 5,356,467 | A | 10/1994 | Oshlack et al. | 6,559,159 | B2 | 5/2003 | Carroll et al. | |
| 5,368,852 | A | 11/1994 | Umamoto et al. | 6,572,885 | B2 | 6/2003 | Oshlack et al. | |
| 5,376,705 | A | 12/1994 | Leys et al. | 6,593,367 | B1 | 7/2003 | Dewey et al. | |
| 5,378,474 | A | 1/1995 | Morella et al. | 6,627,635 | B2 | 9/2003 | Palermo et al. | |
| 5,403,868 | A | 4/1995 | Reid et al. | 6,696,088 | B2 | 2/2004 | Oshlack et al. | |
| 5,409,944 | A | 4/1995 | Black et al. | 6,733,783 | B2 | 5/2004 | Oshlack et al. | |
| 5,411,745 | A | 5/1995 | Oshlack et al. | 6,808,720 | B2 | 10/2004 | Unger | 424/450 |
| 5,422,123 | A | 6/1995 | Conte et al. | 6,995,169 | B2 | 2/2006 | Chapleo et al. | |
| 5,436,265 | A | 7/1995 | Black et al. | 7,141,250 | B2 | 11/2006 | Oshlack et al. | |
| 5,472,712 | A | 12/1995 | Oshlack et al. | 7,144,587 | B2 | 12/2006 | Oshlack et al. | |
| 5,472,943 | A | 12/1995 | Crain et al. | 7,157,103 | B2 | 1/2007 | Sackler | |
| 5,474,995 | A | 12/1995 | Ducharme et al. | 7,201,920 | B2 | 4/2007 | Kumar et al. | |
| 5,478,577 | A | 12/1995 | Sackler et al. | 7,332,182 | B2 | 2/2008 | Sackler | |
| 5,500,227 | A | 3/1996 | Oshlack et al. | 7,727,557 | B2 | 6/2010 | Sackler | |
| 5,502,058 | A | 3/1996 | Mayer et al. | 7,776,314 | B2 | 8/2010 | Bartholomaus | |
| 5,505,959 | A | 4/1996 | Tachon et al. | 7,842,307 | B2 | 11/2010 | Oshlack et al. | |
| 5,508,042 | A | 4/1996 | Oshlack et al. | 7,943,174 | B2 | 5/2011 | Oshlack et al. | |
| 5,510,368 | A | 4/1996 | Lau et al. | 8,017,148 | B2 | 9/2011 | Sackler | |
| 5,514,680 | A | 5/1996 | Weber et al. | 8,075,872 | B2 | 12/2011 | Arkenau-Maric | |
| 5,521,213 | A | 5/1996 | Prasit et al. | 8,101,630 | B2 | 1/2012 | Kumar et al. | |
| 5,536,752 | A | 7/1996 | Ducharme et al. | 8,114,383 | B2 | 2/2012 | Bartholomaus | |
| 5,549,912 | A | 8/1996 | Oshlack et al. | 8,114,384 | B2 | 2/2012 | Arkenau | |
| 5,550,142 | A | 8/1996 | Ducharme et al. | 8,192,722 | B2 | 6/2012 | Arkenau-Maric | |
| 5,552,422 | A | 9/1996 | Gauthier et al. | 8,309,060 | B2 | 11/2012 | Bartholomaus et al. | |
| 5,556,838 | A | 9/1996 | Mayer et al. | 8,337,888 | B2 | 12/2012 | Wright et al. | |
| 5,580,578 | A | 12/1996 | Oshlack et al. | 8,389,007 | B2 | 3/2013 | Wright et al. | |
| 5,593,695 | A | 1/1997 | Merrill et al. | 8,524,275 | B2 | 9/2013 | Oshlack et al. | |
| | | | | 8,529,948 | B1 | 9/2013 | Wright et al. | |
| | | | | 8,609,683 | B2 | 12/2013 | Wright et al. | |
| | | | | 8,652,497 | B2 | 2/2014 | Sackler | |
| | | | | 8,652,515 | B2 | 2/2014 | Sackler | |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | |
|--------------|------|---------|----------------------|---------|
| 8,871,265 | B2 | 10/2014 | Wright et al. | |
| 2003/0004177 | A1 | 1/2003 | Kao et al. | |
| 2003/0021841 | A1 | 1/2003 | Matharu et al. | |
| 2003/0026838 | A1 | 2/2003 | Farrell | |
| 2003/0035839 | A1 | 2/2003 | Hirsh et al. | |
| 2003/0054027 | A1 * | 3/2003 | Unger | 424/450 |
| 2003/0059471 | A1 | 3/2003 | Compton et al. | |
| 2003/0064099 | A1 | 4/2003 | Oshlack et al. | |
| 2003/0064122 | A1 | 4/2003 | Goldberg et al. | |
| 2003/0068276 | A1 | 4/2003 | Hughes et al. | |
| 2003/0068370 | A1 | 4/2003 | Sackler | |
| 2003/0068371 | A1 | 4/2003 | Oshlack et al. | |
| 2003/0068375 | A1 | 4/2003 | Wright et al. | |
| 2003/0068392 | A1 | 4/2003 | Sackler | |
| 2003/0082230 | A1 | 5/2003 | Baichwal et al. | |
| 2003/0124061 | A1 | 7/2003 | Roberts | |
| 2003/0124185 | A1 | 7/2003 | Oshlack et al. | |
| 2003/0125347 | A1 | 7/2003 | Anderson et al. | |
| 2003/0126428 | A1 | 7/2003 | Liu et al. | |
| 2003/0170181 | A1 | 9/2003 | Midha | |
| 2003/0232081 | A1 | 12/2003 | Doshi et al. | |
| 2004/0047907 | A1 | 3/2004 | Oshlack et al. | |
| 2004/0126428 | A1 | 7/2004 | Hughes et al. | |
| 2004/0131552 | A1 | 7/2004 | Boehm | |
| 2004/0151791 | A1 | 8/2004 | Mayo-Alvarez et al. | |
| 2004/0224020 | A1 | 11/2004 | Schoenhard | |
| 2004/0228802 | A1 | 11/2004 | Chang et al. | |
| 2004/0241234 | A1 | 12/2004 | Vilkov | |
| 2004/0253310 | A1 | 12/2004 | Fischer et al. | |
| 2004/0266807 | A1 | 12/2004 | Oshlack et al. | |
| 2005/0020613 | A1 | 1/2005 | Boehm et al. | |
| 2005/0031546 | A1 | 2/2005 | Bartholomaeus et al. | |
| 2005/0063909 | A1 | 3/2005 | Wright et al. | |
| 2005/0106249 | A1 | 5/2005 | Hwang et al. | |
| 2005/0112067 | A1 | 5/2005 | Kumar et al. | |
| 2005/0112201 | A1 | 5/2005 | Baichwal et al. | |
| 2005/0118267 | A1 | 6/2005 | Baichwal et al. | |
| 2005/0158382 | A1 | 7/2005 | Cruz et al. | |
| 2005/0163717 | A1 | 7/2005 | Anderson et al. | |
| 2005/0186139 | A1 | 8/2005 | Bartholomaeus | |
| 2005/0214223 | A1 | 9/2005 | Bartholomaeus et al. | |
| 2005/0236741 | A1 | 10/2005 | Arkenau | |
| 2005/0276853 | A1 | 12/2005 | Baichwal et al. | |
| 2006/0002860 | A1 | 1/2006 | Bartholomaeus | |
| 2006/0018837 | A1 | 1/2006 | Preston et al. | |
| 2006/0039864 | A1 | 2/2006 | Bartholomaeus | |
| 2006/0165790 | A1 | 7/2006 | Walden et al. | |
| 2006/0188447 | A1 | 8/2006 | Arkenau-Maric | |
| 2006/0193782 | A1 | 8/2006 | Bartholomaeus | |
| 2006/0251721 | A1 | 11/2006 | Cruz et al. | |
| 2007/0003616 | A1 | 1/2007 | Arkenau-Maric | |
| 2007/0003617 | A1 | 1/2007 | Fischer et al. | |
| 2007/0110807 | A1 | 5/2007 | Vergnault et al. | |
| 2007/0166234 | A1 | 7/2007 | Kumar et al. | |
| 2007/0264327 | A1 | 11/2007 | Kumar et al. | |
| 2008/0063725 | A1 | 3/2008 | Guimberteau et al. | |
| 2008/0095843 | A1 | 4/2008 | Nutalapati et al. | |
| 2008/0176955 | A1 | 7/2008 | Heck et al. | |
| 2008/0254123 | A1 | 10/2008 | Fischer et al. | |
| 2008/0260815 | A1 | 10/2008 | Hayes et al. | |
| 2009/0081290 | A1 | 3/2009 | McKenna et al. | |
| 2009/0169587 | A1 | 7/2009 | Baichwal et al. | |
| 2009/0215808 | A1 | 8/2009 | Yum et al. | |
| 2010/0221293 | A1 | 9/2010 | Cruz et al. | |
| 2011/0262532 | A1 | 10/2011 | Oshlack et al. | |
| 2012/0164220 | A1 | 6/2012 | Huang | |

FOREIGN PATENT DOCUMENTS

| | | | |
|----|----------------|------|--------|
| EP | 1293195 | A1 | 3/2003 |
| WO | 01/07950 | | 6/1991 |
| WO | WO 93/10765 | A1 * | 6/1993 |
| WO | 95/20947 | | 8/1995 |
| WO | WO-2005/020947 | A1 | 8/1995 |

| | | | |
|----|----------------|----|---------|
| WO | 97/37689 | | 10/1997 |
| WO | 97/48385 | | 12/1997 |
| WO | 97/49384 | | 12/1997 |
| WO | 99/32120 | | 7/1999 |
| WO | WO-99/32119 | A1 | 7/1999 |
| WO | 00/33835 | | 6/2000 |
| WO | WO-01/58447 | A1 | 8/2001 |
| WO | 02/087558 | | 11/2002 |
| WO | WO-02/094254 | A2 | 11/2002 |
| WO | WO-03/015531 | A2 | 2/2003 |
| WO | 03/024430 | | 3/2003 |
| WO | WO-03/026743 | A2 | 4/2003 |
| WO | 03/035029 | | 5/2003 |
| WO | WO-03/092676 | A1 | 11/2003 |
| WO | WO-2004/026256 | A2 | 1/2004 |
| WO | WO-2004/026283 | A1 | 4/2004 |
| WO | WO-2004/037259 | A1 | 5/2004 |
| WO | WO-2005/053587 | A1 | 6/2005 |
| WO | 2010078486 | | 7/2010 |

OTHER PUBLICATIONS

Paragraph IV Patent Certification Notice for ANDA 202455 (2011).
Paragraph IV Patent Certification Notice for ANDA 202352 (2011).
Woodburn, K.R., et al., "Vascular Complications of Injecting Drug Misuse", *British Journal of Surgery*, 1996, vol. 83, p. 1329-1334.
Kim, C., "Drug Release from Compressed Hydrophilic POLYOX-WSR Tablets", *Journal of Pharmaceutical Sciences*, vol. 84, No. 3, Mar. 1995, p. 303-306.
Apicella, A., "Poly(ethylene oxide) (PEO) and Different Molecular Weight PEO Blends Monolithic Devices for Drug Release", *Biomaterials*, vol. 14, No. 2, 1993, p. 83-90.
Deighan, C.J., et al., "Rhabdomyolysis and Acute Renal Failure Resulting From Alcohol and Drug Abuse", *QJ Med*, vol. 93, 2000, p. 29-33.
Kalant, H., et al., "Death in Amphetamine Users: Causes and Rates", *CMA Journal*, vol. 112, Feb. 8, 1975, p. 299-304.
U.S. Pharmacopeia, p. 2206, 1995.
Findings of Fact and Conclusions of Law, In re: Oxycontin Antitrust Litigation, Case 1:04-md-01603-SHS, Jan. 14, 2014.
Moroni, et al., "Application of Poly(oxyethylene) Homopolymers in Sustained Release Solid Formulations", *Drug Dev. and Indus. Pharmacy*, 21(12), 1411-28 (1995).
Apicella, et al., "Poly(ethylene oxide) (PEO) Constant Release Monolithic Devices," *Polymers in Medicine: Biomedical and Pharmaceutical Applications*, Chapter 3 (1992).
Apicella, et al., "Poly(ethylene oxide)-Based Delivery Systems", *Polymeric Drugs and Drug Administration*, ACS Symposium Series 545, Chapter 9 (1994).
Zhang, F, et al., "Properties of Sustained-Release Tablets Prepared by Hot-Melt Extrusion", *Pharmaceutical Development and Technology*, vol. 4, No. 2, p. 241-250 (1999).
Maggi, L., et al., "Dissolution Behaviour of Hydrophilic Matrix Tablets Containing Two Different Polyethylene Oxides (PEOs) for the Controlled Release of a Water-Soluble Drug", *Biomaterials*, vol. 23, p. 1113-1119 (2002).
Paragraph IV Patent Certification Notice for ANDA 202455 (2013).
Written Opinion and International Search Report for International Patent Application No. PCT/IB2011/003152 issued Sep. 19, 2012.
U.S. Appl. No. 13/333,560—Non-Final Rejection dated Jan. 29, 2013.
U.S. Appl. No. 13/333,560—Amendment/Response dated Apr. 29, 2013.
Opinion & Order filed May 27, 2014, Case 1:04-md-01603-SHS, 24 pgs.
Declaration of Interference No. 106,004 filed Apr. 22, 2014, 8 pgs.
USPTO Final Rejection for U.S. Appl. No. 13/765,368 dated Mar. 12, 2014.
USPTO Response for U.S. Appl. No. 13/765,368 dated Jan. 6, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 13/765,368 dated Oct. 4, 2013.
USPTO Final Rejection for U.S. Appl. No. 13/946,418 dated Apr. 10, 2014.
USPTO Response for U.S. Appl. No. 13/946,418 dated Dec. 12, 2013.

(56)

References Cited

OTHER PUBLICATIONS

USPTO Non-Final Rejection for U.S. Appl. No. 13/946,418 dated Sep. 12, 2013.
USPTO Final Rejection for U.S. Appl. No. 13/890,874 dated Mar. 11, 2014.
USPTO Response for U.S. Appl. No. 13/890,874 dated Feb. 28, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 13/890,874 dated Dec. 18, 2013.
USPTO Response for U.S. Appl. No. 13/726,324 dated Jan. 15, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 13/726,324 dated Jul. 15, 2013.
Complaint 1:13-cv-01272-SHS (Feb. 25, 2013).
Answer and Counterclaims 1:13-cv-01272-SHS (Mar. 8, 2013).
Answer to Counterclaims 1:13-cv-01272-SHS (Apr. 1, 2013).
Consent Judgement :13-cv-01272-SHS (May 1, 2013).
Complaint 1:13-cv-03188-SHS (May 10, 2013).
Answer; Affirmative Defenses and Counterclaims 1:13-cv-03188-SHS (Jun. 7, 2013).
Complaint 1:13-cv-03374-SHS (May 17, 2013).
Answer and Counterclaims 1:13-cv-03374-SHS (Jun. 3, 2013).
Complaint 1:13-cv-03372-SHS (May 17, 2013).
Paragraph IV Patent Certification Notice for ANDA 202352 (2013).
Paragraph IV Patent Certification Notice for ANDA 202372 (2013).
Paragraph IV Patent Certification Notice for ANDA 202434 (2013).
Paragraph IV Patent Certification Notice for ANDA 202483 (2013).
Paragraph IV Patent Certification Notice for ANDA 203235 (2013).
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (2010). Prescribing Information for Concerta Extended-Release Tablets.
Bettini et al., "Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate," Journal of Controlled Release, vol. 70, No. 3, Feb. 2001, pp. 383-391.

Medical Economics Company, Inc., The 1997 Physician's Desk Reference ("PDR") entry for OXYCONTIN®, 51st edition, Nov. 1996, Montvale, NJ, pp. 2163-2164.
Sarkar, N., "Kinetics of thermal gelation of methylcellulose and hydroxypropylmethylcellulose in aqueous solutions," Carbohydrate Polymers, vol. 26, No. 3, Jan. 1995, pp. 195-203.
Sarkar, N., "Thermal Gelation Properties of Methyl and Hydroxypropyl Methylcellulose," Journal of Applied Polymer Science, vol. 24, No. 4, Aug. 1979, pp. 1073-1087.
Wilkins, Jeffrey, N., "Pharmacotherapy of Schizophrenia Patients with Comorbid Substance Abuse", Schizophrenia Bulletin, vol. 23, No. 2, 1997, <http://schizophreniabulletin.oxfordjournals.org>, pp. 215-228.
Yang, et al., "Characterization of Compressibility and Compactibility of Poly(ethylene oxide) Polymers for Modified Release Application by Compaction Simulator", Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996, pp. 1085-1090.
Complaint for Case 1:13-cv-04606, Jul. 2, 2013, pp. 11.
Paragraph IV Patent Certification Notice for ANDA 203915, Jul. 26, 2013, pp. 63.
USPTO Non-Final Rejection for U.S. Appl. No. 14/243,580, dated Oct. 2, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 14/460,170, dated Oct. 2, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 14/470,631, dated Oct. 21, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 14/470,662, dated Nov. 4, 2014.
USPTO Non-Final Rejection for U.S. Appl. No. 14/484,077, dated Oct. 22, 2014.
Findings of Fact and Conclusions of Law, In re: Oxycontin Antitrust Litigation, Case 1:04-md-01603-SHS, Apr. 8, 2015, pp. 1-69.

* cited by examiner

1

**PHARMACEUTICAL FORMULATION
CONTAINING GELLING AGENT**

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/255,502, filed Apr. 17, 2014, which is a continuation of U.S. patent application Ser. No. 13/726,324, filed Dec. 24, 2012, which is a continuation of U.S. patent application Ser. No. 13/349,449, filed Jan. 12, 2012, now issued as U.S. Pat. No. 8,337,888, which is a continuation of U.S. patent application Ser. No. 12/653,115, filed Dec. 8, 2009, which is a continuation of U.S. patent application Ser. No. 10/214,412, filed Aug. 6, 2002, which claims the benefit of U.S. Provisional Application No. 60/310,534, filed Aug. 6, 2001. The contents of these applications are hereby incorporated by reference in their entirety.

BACKGROUND OF THE INVENTION

Opioid analgesics are sometimes the subject of abuse. Typically, a particular dose of an opioid analgesic is more potent when administered parenterally as compared to the same dose administered orally. Therefore, one popular mode of abuse of oral opioid formulations involves the extraction of the opioid from the dosage form, and the subsequent injection of the opioid (using any "suitable" vehicle for injection) in order to achieve a "high." Also, some formulations can be tampered with in order to provide the opioid agonist contained therein better available for illicit use. For example, a controlled release opioid agonist formulation can be crushed in order to provide the opioid contained therein available for immediate release upon oral or nasal administration. An opioid formulation can also be abusable by administration of more than the prescribed dose of the drug.

Opioid antagonists have been combined with certain opioid agonists in order to deter the parenteral abuse of opioid agonists. In the prior art, the combination of immediate release pentazocine and naloxone has been utilized in tablets available in the United States, commercially available as Talwin®Nx from Sanofi-Winthrop. Talwin®Nx contains immediate release pentazocine hydrochloride equivalent to 50 mg base and naloxone hydrochloride equivalent to 0.5 mg base. A fixed combination therapy comprising tilidine (50 mg) and naloxone (4 mg) has been available in Germany for the management of pain since 1978 (Valoron®N, Goedecke). A fixed combination of buprenorphine and naloxone was introduced in 1991 in New Zealand (Temgesic®Nx, Reckitt & Colman) for the treatment of pain.

Purdue Pharma EP currently markets sustained-release oxycodone in dosage forms containing 10, 20, 40, and 80 mg oxycodone hydrochloride under the tradename OxyContin.

U.S. Pat. Nos. 5,266,331; 5,508,042; 5,549,912 and 5,656,295 disclose sustained release oxycodone formulations.

U.S. Pat. Nos. 4,769,372 and 4,785,000 to Kreek describe methods of treating patients suffering from chronic pain or chronic cough without provoking intestinal dysmotility by administering 1 to 2 dosage units comprising from about 1.5 to about 100 mg of opioid analgesic or antitussive and from about 1 to about 18 mg of an opioid antagonist having little to no systemic antagonist activity when administered orally, from 1 to 5 times daily.

U.S. Pat. No. 6,228,863 to Palermo et al. describes compositions and methods of preventing abuse of opioid dosage forms.

WO 99/32119 to Kaiko et al. describes compositions and methods of preventing abuse of opioid dosage forms.

2

U.S. Pat. No. 5,472,943 to Crain et al. describes methods of enhancing the analgesic potency of bimodally acting opioid agonists by administering the agonist with an opioid antagonist.

U.S. Pat. No. 3,980,766 to Shaw et al., is related to drugs which are suitable for therapy in the treatment of narcotic drug addiction by oral use, e.g., methadone, formulated to prevent injection abuse through concentration of the active component in aqueous solution by incorporating in a solid dosage or tablet form of such drug an ingestible solid having thickening properties which cause rapid increase in viscosity upon concentration of an aqueous solution thereof.

However, there still exists a need for a safe and effective treatment of pain with opioid analgesic dosage forms which are less subject to abuse than current therapies.

All documents cited herein, including the foregoing, are incorporated by reference in their entireties for all purposes.

OBJECTS AND SUMMARY OF THE
INVENTION

It is an object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less parenteral abuse than other dosage forms.

It is an object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less intranasal abuse than other dosage forms.

It is an object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less oral abuse than other dosage forms.

It is a further object of certain embodiments of the invention to provide an oral dosage form of an opioid analgesic which is subject to less diversion than other dosage forms.

It is a further object of certain embodiments of the invention to provide a method of treating pain in human patients with an oral dosage form of an opioid analgesic while reducing the abuse potential of the dosage form.

It is a further object of certain embodiments of the invention to provide a method of manufacturing an oral dosage form of an opioid analgesic such that it has less abuse potential.

These objects and others are achieved by the present invention, which is directed in part to an oral dosage form comprising an opioid analgesic; and at least one aversive agent for reducing the abuse of the opioid analgesic.

In certain embodiments of the present invention, the oral dosage forms of the present invention comprising an opioid analgesic; and an aversive agent or agents as a component(s) of the dosage form helps to prevent injection, inhalation, and/or oral abuse by decreasing the "attractiveness" of the dosage form to a potential abuser.

In certain embodiments of the present invention, the dosage form comprises an aversive agent such as a bittering agent to discourage an abuser from tampering with the dosage form and thereafter inhaling or swallowing the tampered dosage form. Preferably, the bittering agent is released when the dosage form is tampered with and provides an unpleasant taste to the abuser upon inhalation and/or swallowing of the tampered dosage form.

In certain embodiments of the present invention, the dosage form comprises an aversive agent such as an irritant to discourage an abuser from tampering with the dosage form and thereafter inhaling, injecting, or swallowing the tampered dosage form. Preferably, the irritant is released when the dosage form is tampered with and provides a burning or irritating effect to the abuser upon inhalation, injection, and/or swallowing of the tampered dosage form.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.